Vanta Bioscience

Vanta Bioscience EBITDA per Share

The EBITDA per Share of Vanta Bioscience (540729.BO) as of Oct 26, 2026 is -6.74 INR. In the previous year, EBITDA per Share was 2.08 INR — a change of -424.22% (lower).

EBITDA per Share

-6.74INR

YoY

-424.22%

Last updated:

EBITDA per Share of Vanta Bioscience is 2025 -6.74 INR. EBITDA per Share of Vanta Bioscience was 2024 2.08 INR. It decreases by -424.22% lower compared to the previous year.

The Vanta Bioscience EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
1.89 INR
Jan 1, 2019
5.92 INR
Jan 1, 2020
6.92 INR
Jan 1, 2021
6.34 INR
Jan 1, 2022
5.49 INR
Jan 1, 2023
-3.79 INR
Jan 1, 2024
2.08 INR
Jan 1, 2025
-6.74 INR
The Vanta Bioscience EBITDA per Share history
YEAREBITDA per ShareYoY
-6.74INR-424.22%
2.08INR-154.84%
-3.79INR-169.02%
5.49INR-13.28%
6.34INR-8.46%
6.92INR+17.00%
5.92INR+213.36%
1.89INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vanta Bioscience Stock analysis

What does Vanta Bioscience do? Vanta Bioscience Ltd. generates revenue by offering comprehensive preclinical contract research services to pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. The company provides preclinical safety assessment services, risk assessment for active pharmaceutical ingredients (API), excipients, extractable and leachable substances, and pharmaceutical impurities. It also delivers health-based exposure limit determinations including permitted daily exposure (PDE), allowable daily exposure (ADE), and occupational exposure limits (OEL) for pharmaceutical manufacturers. The firm's clients across diverse sectors rely on its analytical testing, environmental studies, and research services for regulatory compliance and product safety validation. Vanta Bioscience Ltd. operates as a full-service preclinical contract research organization with a focus on delivering specialized safety assessments and exposure limit evaluations to support client product development and market entry. Its service portfolio includes clinical research, pre-clinical research, biopharma services, analytical testing, and environmental studies, catering to industries requiring rigorous safety evaluations before product launch. The company's expertise in risk assessment for pharmaceutical ingredients and related substances enables it to serve a broad range of clients in the biopharma and chemical sectors. Vanta Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vanta Bioscience stock

EBITDA per Share of Vanta Bioscience is -6.74 INR in 2025.

EBITDA per Share of Vanta Bioscience changed from 2.08 INR to -6.74 INR, representing a -424.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Vanta Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Vanta Bioscience

All Key Metrics — Vanta Bioscience